Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-04-29 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
CHANGE OF REGISTERED ADDRESS AND ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN THE PRC AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Board/Management Information Classification · 95% confidence The document is an announcement from Yanzhou Coal Mining Company Limited regarding a change of registered address and principal place of business, as well as proposed amendments to the Articles of Association. It includes details about the change in street number, the company's promoter's name change, and specific amendments to the articles. There are no financial statements, earnings data, or detailed management discussion. The document is a formal announcement of corporate changes and proposed amendments to governance documents, not a full report or financial filing. It is not a report publication announcement since it contains substantive content about the amendments and address change. This fits best under Board/Management Information (MANG) as it relates to corporate governance changes and company administrative updates.
2021-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-04-29 English
2020 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is a comprehensive report from CStone Pharmaceuticals covering a full fiscal year, including detailed financial highlights, corporate information, management discussion and analysis, directors' report, corporate governance report, independent auditor's report, and full consolidated financial statements with notes. The presence of a full set of financial statements, auditor's report, and extensive management commentary indicates this is a full annual report. The document references the year ended December 31, 2020, consistent with an annual reporting period. It is not a brief announcement or a partial report, nor is it a transcript, presentation, or regulatory filing. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-04-27 English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NDA OF SELECTIVE RET INHIBITOR GAVRETO (PRALSETINIB) WITH PRIORITY REVIEW DESIGNATION FOR THE TREATMENT OF ADVANCED OR METASTATIC RET-ALTERED THYROID CANCER
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the acceptance of a New Drug Application (NDA) by the National Medical Products Administration (NMPA) of China for a selective RET inhibitor drug, GAVRETO (Pralsetinib), with priority review designation. The content focuses on regulatory acceptance, clinical trial results, drug approval status, and company background. It does not contain financial statements, detailed financial performance data, or management discussion of financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing in the sense of officer certifications or compliance documents, but rather a corporate announcement about a regulatory milestone related to drug approval. The document is longer than 5,000 characters and contains substantive information about the NDA acceptance, clinical trial data, and drug details, which is typical of a Capital/Financing Update or Regulatory Announcement related to product development and regulatory progress. Given the focus on the NDA acceptance and priority review designation, this fits best under Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, and also significant corporate developments such as regulatory approvals or submissions that impact company valuation and capital markets. Therefore, the most appropriate classification is CAP with high confidence.
2021-04-26 English
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2021 SECOND TRANCHE OF SUPER-SHORT-TERM BONDS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of the issuance of a tranche of super-short-term bonds by Yanzhou Coal Mining Company Limited. It includes details such as issuance amount, interest rate, term, and underwriters. The document is relatively short (3007 characters) and serves as a formal announcement of a financing activity rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-04-23 English
NNOUNCEMENT ON THE APPROVAL OF REGISTRATION OF THE ISSUANCE OF FINANCING INSTRUMENTS
Capital/Financing Update Classification · 95% confidence The document is an announcement from Yanzhou Coal Mining Company Limited regarding the approval of registration for the issuance of financing instruments. It references regulatory compliance with the Securities and Futures Ordinance and listing rules of the Hong Kong Stock Exchange. The content focuses on the approval to carry out domestic and overseas financing activities, including issuing various bonds and financial instruments. There is no detailed financial data, financial statements, or comprehensive report content. The document is relatively short (2855 characters) and serves as an official announcement of a financing approval rather than a full financing report or detailed capital update. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2021-04-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.